Debora Martorelli

ORCID: 0000-0001-7385-3571
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Viral-associated cancers and disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Immunotherapy and Biomarkers
  • Cytomegalovirus and herpesvirus research
  • Parvovirus B19 Infection Studies
  • HIV Research and Treatment
  • Respiratory viral infections research
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cell Adhesion Molecules Research
  • Cancer-related molecular mechanisms research
  • Virus-based gene therapy research
  • RNA Interference and Gene Delivery
  • T-cell and B-cell Immunology
  • Cancer-related Molecular Pathways
  • Cancer Treatment and Pharmacology
  • Brain Metastases and Treatment
  • T-cell and Retrovirus Studies
  • Retinoids in leukemia and cellular processes
  • Systemic Lupus Erythematosus Research
  • Immunodeficiency and Autoimmune Disorders

Exosome Diagnostics (United States)
2024

Centro di Riferimento Oncologico
2013-2023

Istituti di Ricovero e Cura a Carattere Scientifico
2010-2023

National Cancer Institute
2014

Oncology Institute of Vojvodina
2012

MRC Epidemiology Unit
2007

Hashimoto's thyroiditis (HT) is the most common of all thyroid diseases and characterized by abundant lymphocyte infiltrate impairment, caused various cell- antibody-mediated immune processes. Viral infections have been suggested as possible environmental triggers, but conclusive data are not available. We analyzed presence transcriptional state human herpesvirus 6 (HHV-6) in fine needle aspirates (FNA) peripheral blood mononuclear cells (PBMCs) from 34 HT patients 28 controls, showing that...

10.1371/journal.ppat.1002951 article EN cc-by PLoS Pathogens 2012-10-04

Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency these together with the immune-modulating activities NC drugs suggest potential contribution host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring locally BC undergoing to identify immunological correlates pCR induction.The profile 40 HER2-positive...

10.1186/s12967-015-0567-0 article EN cc-by Journal of Translational Medicine 2015-06-26

Local irradiation of cancer through radiotherapy can induce spontaneous regression non-directly irradiated lesions, suggesting the involvement systemic antitumor immune responses. In oligometastatic breast (BC) patients, use stereotactic body (SBRT) favors local control treated lesions and may contribute to break tolerance release tumor-associated antigens (TAAs), improving host immunity. We performed a detailed immunomonitoring BC patients undergoing SBRT verify its ability "switch on"...

10.3389/fimmu.2017.01476 article EN cc-by Frontiers in Immunology 2017-11-06

Cell-free microRNA (miRNA) in biofluids released by tumors either protein or vesicle-bound form, represent promising minimally-invasive cancer biomarkers. However, a highly abundant non-tumor background human plasma and serum complicates the discovery detection of tumor-selective circulating miRNAs. We performed small RNA sequencing on from Nasopharyngeal Carcinoma (NPC) patients. Collectively, Epstein Barr virus-encoded miRNAs, more so than endogenous signify presence NPC. RNAseq-based EBV...

10.1002/ijc.31967 article EN cc-by-nc International Journal of Cancer 2018-11-09

Although promising, the clinical benefit provided by dendritic cell (DC)-based vaccines is still limited and choice of optimal antigen formulation an unresolved issue. We have developed a new DC-based vaccination protocol for aggressive and/or refractory lymphomas which combines unique features interferon-conditioned DC (IFN-DC) with highly immunogenic tumor lysates (TCL) obtained from lymphoma cells undergoing death. show that treatment mantle (MCL) diffuse large B-cell (DLBCL) lines...

10.1080/2162402x.2017.1356964 article EN OncoImmunology 2017-07-31

This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated monocyte-derived dendritic cells generated presence of IFNα GM-CSF (IFN-DC) combination low doses rituximab.Firstly, we analyzed vitro vivo properties IFN-DC against lymphoma. Thus, performed a phase I trial 8 refractory relapsed based on sequential intranodal injections low-dose rituximab unloaded report clinical, results enrolled patients.Preclinical...

10.1158/1078-0432.ccr-19-0709 article EN Clinical Cancer Research 2019-06-06

Human immunodeficiency virus p17 matrix protein is released by infected cells and may accumulate within lymphoid tissues where it deregulate the biological activities of different cell populations binding to CXCR1 CXCR2 cellular receptors. S75X, a natural variant, was recently shown enhance malignant properties lymphoma cells. We investigated reference S75X variant for their ability bind Epstein-Barr (EBV)-infected primary fully transformed B-lymphocytes trigger downstream effects potential...

10.1002/ijc.29494 article EN International Journal of Cancer 2015-02-23

The clinical efficacy of trastuzumab and taxanes is at least partly related to their ability mediate or promote antitumor immune responses. On these grounds, a careful analysis basal profile may be capital dissect the heterogeneity responses drugs in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Blood samples were collected from 61 cancers (36 HER2- 25 HER2+) diagnosis 23 healthy women. Immunophenotypic profiling circulating intratumor cells, including...

10.1186/bcr3060 article EN cc-by Breast Cancer Research 2011-11-23

Silencing of tumor suppressor genes (TSGs) or activation oncogenes by, e.g., aberrant promoter methylation, may be early events during carcinogenesis. The methylation status such can used for detection cancer. We are pursuing this approach in our efforts to develop markers and follow-up nasopharyngeal carcinoma (NPC). set out allow identification NPC from Morocco then also compared with samples different geographical locations ethnicity incidences, Epstein-Barr virus (EBV) prevalence,...

10.1186/s13148-015-0119-8 article EN cc-by Clinical Epigenetics 2015-08-21

Abstract Immunotherapy approaches targeting Epstein‐Barr virus (EBV)‐encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized immunogenicity EBV‐encoded BARF1 oncogene aim to assess whether this protein could constitute new target antigen for immunotherapy setting. Spontaneous CD4+ and CD8+ T cell specific recombinant p29 were detected by IFN γ ‐ELISPOT both...

10.1002/ijc.23621 article EN International Journal of Cancer 2008-06-10

Abstract Mantle cell lymphoma (MCL) is characterized by a profound deregulation of the mechanisms controlling cell-cycle progression and survival. We herein show that combination 9-cis-retinoic acid (RA) IFN-α induces marked antiproliferative proapoptotic effects in MCL cells through modulation critical targets. Particularly, enhances RA-mediated G0–G1 accumulation downregulating cyclin D1 increasing p27Kip1 p21WAF1/Cip1 protein levels. Furthermore, RA/IFN-α also apoptosis triggering both...

10.1158/0008-5472.can-11-2505 article EN Cancer Research 2012-02-07

ABSTRACT Exogenous HIV-1 matrix protein p17 (p17) deregulates the function of different cells after its N-terminal loop (AT20) binding to chemokine receptors CXCR1 and CXCR2. One site within AT20 has been recently found be major determinant viral fitness following transmission simian immunodeficiency virus (SIV) human host. Therefore, we sought determine whether SIV (MA) was already capable interacting with CXCR2 mimic biological activities rather than this being a newly acquired during host...

10.1128/jvi.03142-13 article EN Journal of Virology 2014-03-13

Although promising, clinical responses to adoptive immunotherapy for nasopharyngeal carcinoma (NPC) are still limited by the restricted number of Epstein-Barr virus (EBV) antigens that can be targeted and their poor immunogenicity. Our previous work indicated immunogenic features NPC-associated viral antigen BARF1 may exploited immunotherapeutic purposes. Nevertheless, T-cell lines obtained with current protocols include only negligible numbers BARF1-specific cytotoxic T lymphocytes,...

10.1158/2326-6066.cir-15-0108 article EN Cancer Immunology Research 2016-03-24

Abstract Background Engagement of CD40 promotes survival undifferentiated nasopharyngeal carcinoma (UNPC) cells and similar effects are induced by the EBV oncoprotein LMP-1 that is expressed in a fraction cases. Considering may be activated also soluble isoform CD40L (sCD40L), we investigated serum levels sCD40L series 61 UNPC patients from Italy, non-endemic area for this disease. Results At diagnosis, samples contained significantly higher than age-matched healthy controls (p < 0.001)....

10.1186/1750-9378-2-5 article EN cc-by Infectious Agents and Cancer 2007-03-01

The role of genetic factors involved in the development undifferentiated nasopharyngeal carcinoma (UNPC) nonendemic areas has been poorly investigated. High-resolution human leukocyte antigen (HLA) class I genotyping carried out 82 Italian UNPC patients and 286 bone marrow donors born same province showed that A*0201, B*1801, B*3501, known to efficiently present Epstein-Barr virus (EBV)-derived epitopes, were significantly under-represented patients. Moreover, A*0201/B*1801 haplotype was...

10.1002/ijc.24515 article EN International Journal of Cancer 2009-04-22

An increasing set of B-cell non-Hodgkin lymphomas (B-NHL) show a biased usage IGKV3-20 and IGKV3-15 immunoglobulin genes, feature that could be exploited for the development ready-to-use, broadly applicable cancer vaccines.The immunogenic properties clonal proteins were analyzed with particular focus on their ability to elicit cross-reactive responses against molecularly related IGKV expressed by different lymphoproliferative disorders.IGK+ lymphoma patients humoral T-cell IGKV3-specific...

10.1158/1078-0432.ccr-12-0763 article EN Clinical Cancer Research 2012-06-17
Coming Soon ...